← Back to Search

MRSA Nasal Swab for Community-acquired Pneumonia (STOP-Vanc Trial)

N/A

Waitlist Available

Led By Jeffrey Freiberg, MD, PhD

Research Sponsored by Vanderbilt University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Suspicion for pneumonia on admission (defined as an indication for antibiotics of 'respiratory infection' and/or an order for a respiratory culture i.e., sputum culture, tracheal aspirate culture, or bronchoalveolar lavage (BAL) culture)

Must match both of the following in either order: 1) The patient has been admitted to and physically located in the MICU. 2) The patient has received a continuing vancomycin order, or a pharmacokinetics consult for a continuing vancomycin order, no later than 24 hours following their physical admission to the MICU.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up thirty days following enrollment.

Awards & highlights

STOP-Vanc Trial Summary

This trial will see if alerting healthcare providers about negative rapid PCR results through a pager can help reduce the use of vancomycin in critically ill adults with community-acquired pneumonia compared to the standard care

Who is the study for?

Adults over 18 with suspected pneumonia, admitted to Vanderbilt University Medical Center's MICU from the ER or hospital floor within 48 hours. They must be in the MICU and on vancomycin without prior nasal decolonization. Prisoners or those hospitalized for over 48 hours before MICU admission are excluded.Check my eligibility

What is being tested?

The study tests if a rapid PCR swab alerting doctors of negative MRSA results can reduce vancomycin use in critically ill adults with community-acquired pneumonia, compared to standard care without such alerts.See study design

What are the potential side effects?

This trial primarily involves diagnostic testing rather than medication; therefore, side effects may include discomfort or minor bleeding from the nasal swab procedure.

STOP-Vanc Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was suspected of having pneumonia when I was admitted.

Select...

I was admitted to the MICU and received a vancomycin order within 24 hours.

STOP-Vanc Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to seven days following enrollment.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to seven days following enrollment.

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to seven days following enrollment. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Vancomycin-free hours alive

Secondary outcome measures

30-day all-cause mortality

Time Alive off Vancomycin

STOP-Vanc Trial Design

2Treatment groups

Active Control

Group I: MRSA Nasal SwabActive Control1 Intervention

Subjects will have a nasal swab collected and sent to the clinical laboratory for the MRSA nasal swab PCR test to be run. For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.

Group II: No MRSA Nasal SwabActive Control1 Intervention

Subjects will not have a nasal swab collected.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor

856 Previous Clinical Trials

671,980 Total Patients Enrolled

1 Trials studying Community-acquired Pneumonia

Jeffrey Freiberg, MD, PhDPrincipal InvestigatorVanderbilt University Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available positions for patients in this ongoing clinical trial?

"The investigation is currently not in the recruitment phase, as indicated by clinicaltrials.gov. The study's posting date was 12/1/2024, with the last update on 2/15/2024. Despite this trial being inactive regarding patient enrollment, there are presently 206 other studies actively seeking participants."

Answered by AI

Recent research and studies

American Journal of Respiratory and Critical Care MedicineJournal

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

Metlay, Joshua P., Grant W. Waterer, Ann C. Long, Antonio Anzueto, Jan Brozek, Kristina Crothers, Laura A. Cooley, et al.. 2019. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine. American Thoracic Society. doi:10.1164/rccm.201908-1581st.

clinicaltrials.govStudy

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin

Jeffrey A Freiberg 2024. "Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06272994.